[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"posterior-vitreous-detachment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:posterior-vitreous-detachment":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100586480","yag-laser-vitreolysis-for-vitreous-floaters-100586480",false,"NCT06915922","YAG Laser Vitreolysis for Vitreous Floaters","Therapeutic Neodymium-doped Yttrium-Aluminum-Garnet (Nd:YAG) Laser Vitreolysis for Vitreous Floaters - A Study to Quantify Visual Quality of Life, Vitreous Structure, and Vision Before and After Nd:YAG Laser Vitreolysis in Patients With Vision Degrading Myodesopsia","YLV Protocol","Inclusion Criteria:\n\n* Only one eye per patient will be included in this study\n* Able and willing to give informed consent\n* Age ≥18 years\n* Suffering from symptomatic vitreous floaters\n* Floaters arising from either\u002Fboth:\n\n  * myopic vitreopathy\n  * posterior vitreous detachment\n* Floaters meeting the following characteristics:\n\n  * Present for ≥3 months\n  * One single or more dense and well-defined vitreous opacities,\n  * A Weiss Ring or opacities which are within the safety area, at least 3mm away from the retina and 6mm away from the lens\n  * Visible on contact lens biomicroscopy\n\nExclusion Criteria:\n\n* Patient presenting with vitreous opacities outside of the described safety area (within 3mm of the retina or 6mm from the lens)\n* Have clinically significant cataract (lens opacification) in one or both eyes which are in the opinion of the examining doctor more significant in impacting vision as compared to that caused by vitreous opacities; or cataract expected to need cataract surgery during the duration of the study\n* Present with untreated retinal tears or retinal holes requiring treatment at the discretion of the study investigator\n* Have high risk of peripheral lesions requiring treatment at the discretion of the study investigator\n* Have synchysis scintillans (unusual vitreous opacities from old blood)\n* Have asteroid hyalosis (unusual vitreous opacities from cholesterol)\n* Have vitreous hemorrhage (fresh blood in the center of the eye)\n* Have active photopsia (flashing lights)\n* History of previous YAG laser vitreolysis treatments, or vitrectomy for any condition (retinal detachment, proliferative diabetic retinopathy, etc.)\n* Have Posterior Vitreous Detachment (separation of vitreous away from the retina lining the inside of the back of the eye) within the past 3 months\n* Are unable to attend study appointments\n* Have any other significant ocular or non-ocular condition that, at the discretion of the study investigator, puts the subject at risk or influences the results of the study\n* History of intraocular surgery within 6 months from study entry\n* History of retinal laser within 2 months from study entry","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to measure how the quality of life, the structure of eye, and vision change after treatment for the opacities in the gel (vitreous) that fills the center of eye which cause vision disturbances commonly called \"floaters\".\n\nIn this study the vitreous floaters are treated using a Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser. The FDA has approved the use of this laser to treat membranes in the eye.",[27,28,29],"Posterior Vitreous Detachment","Myopic Vitreopathy","VISION DEGRADING MYODESOPSIA","RECRUITING","2026-02-23",{"date":33,"type":34},"2026-02-27","ACTUAL",{"date":36,"type":34},"2023-10-17",{"date":38,"type":21},"2026-05",{"name":40,"class":41},"VMR Consulting, Inc.","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":42},"100597996","quantification--classification-of-inflammatory-cells-in-uveitis-using-oct-100597996","NCT07065747","Quantification & Classification of Inflammatory Cells in Uveitis Using OCT","Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography","Inclusion Criteria:\n\n1. Uveitis Group: Eyes with active intraocular inflammation and a clinical diagnose of spondyloarthritis\u002FHLA-B27 associated anterior uveitis, Juvenile Idiopathic Arthritis (JIA) associated chronic anterior uveitis, Herpes Simplex Virus (HSV) anterior uveitis, Birdshot chorioretinitis, Behcet disease uveitis, sarcoidosis associated uveitis, uveitis of any additional type, or uveitis masquerade.\n2. Posterior Vitreous Detachment Group: Eyes with vitreous floaters and posterior vitreous detachment (PVD).\n3. Healthy\u002FControl Group: Healthy eyes with no history of uveitis, PVD, or previous eye surgery.\n\nExclusion Criteria:\n\n1. Inability to give informed consent.\n2. Inability to maintain stable fixation for OCT imaging.\n3. Inability to commit to required visits to complete the study.\n4. Pregnancy and breastfeeding.",true,"5 Years","85 Years",{"count":54,"type":21},125,"OBSERVATIONAL","The goal of this study is to determine if it's possible to use a high resolution imaging device called optical coherence tomography (OCT) to develop an unbiased, standard method of counting and categorizing the various types of cells and proteins found in an eye condition called anterior uveitis. Anterior uveitis is a type of inflammation in the eye that can be caused by many different diseases of the body.",[58,59,60,61,62,63,64,27],"Anterior Uveitis (AU)","Birdshot Chorioretinitis","Behcet Disease","Herpes Simplex Virus","Juvenile Idiopathic Arthritis (JIA)","Spondyloarthritis (SA)","Sarcoidosis","2025-07-14",{"date":67,"type":34},"2025-07-17",{"date":69,"type":34},"2024-09-01",{"date":71,"type":21},"2026-12",{"name":73,"class":41},"Oregon Health and Science University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":50,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":42},"100231450","vitreopapillary-interface-and-optic-disc-morphology-100231450","NCT02290795","Vitreopapillary Interface and Optic Disc Morphology","Vitreopapillary Traction and Optic Disc Morphology in Healthy Subjects, Vitreomacular Traction Patients and Glaucoma Patients","Inclusion Criteria:\n\n* willingness to sign informed consent, aged over 18y, glaucoma\u002Ftrabeculectomy scheduled\u002FOcriplasmin scheduled\u002Fhealthy\n\nExclusion Criteria:\n\n* medical history of vitrectomy\u002Fdiabetes\u002FRetinal Vessel Occlusion",{"count":82,"type":21},350,"The vitreous fills the posterior chamber of the eye and is firmly attached, at the posterior pole, to the macula and the optic nerve head (ONH). With formation of a stepwise posterior vitreous detachment (PVD) exerted tractional forces could influence retinal functioning. Especially in patients with glaucoma the influence of vitreous traction to the ONH could mask progression, interfere with current imaging techniques and even be a cause of ONH hemorrhages. Therefore the aim of this study is to investigate whether vitreopapillary traction has a significant effect on diagnosis and follow up of glaucoma patients.",[27,85,86,87],"Vitreomacular Traction","Glaucoma","Vitreopapillary Traction",[89],"Vitreopapillary traction","2024-07-09",{"date":92,"type":34},"2024-07-10",{"date":94,"type":34},"2014-11",{"date":96,"type":21},"2025-08",{"name":98,"class":41},"Universitaire Ziekenhuizen KU Leuven"]